Clinical trial
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic…
NCT00255658 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00255658 |
|---|---|
| Title | Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors |
| Official title | Phase I, Pharmacokinetic and Pharmacodynamic Study of BAY 43-9006 (Sorafenib) in Combination With CCI-779 (Temsirolimus) in Advanced Solid Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | sorafenib tosylate, temsirolimus, laboratory biomarker analysis |
| Enrollment | 40 |
| Start date | Sep 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Nov 21, 2005 |
| Last update posted | Apr 15, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: